Clinical Trial Update: IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating IGF-I and IGFBP-3 therapy for growth hormone insensitivity syndrome (Laron syndrome) in children and adolescents has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Insensitivity Syndrome
• Laron Syndrome

Drugs mentioned

• IGF-1 Therapy (insulin-like growth factor 1)
• IGFBP-3 therapy (insulin-like growth factor-binding protein 3)

Snippet

Sponsor: Insmed Incorporated | Conditions: Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome | Phase 2, Phase 3 | Status: COMPLETED